|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2010-8-11
|
|
pubmed:abstractText |
Thymidine kinase 1 in serum (STK1) has been found to be a reliable proliferation marker in clinical trials. In this study, we examined the significance of STK1 in routine clinical settings.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
1437-7772
|
|
pubmed:author |
pubmed-author:ChenDedongD,
pubmed-author:ChenYanSongY,
pubmed-author:DaleT JTJ,
pubmed-author:HeEllenE,
pubmed-author:HuMinhuaM,
pubmed-author:LiXiaoliX,
pubmed-author:LinYingyingY,
pubmed-author:SkogSvenS,
pubmed-author:XiaYunY,
pubmed-author:YingMingangM,
pubmed-author:ZhangMingM,
pubmed-author:ZhouJiJ
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
15
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
359-68
|
|
pubmed:dateRevised |
2011-9-13
|
|
pubmed:meshHeading |
pubmed-meshheading:20354751-Adult,
pubmed-meshheading:20354751-Aged,
pubmed-meshheading:20354751-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:20354751-Chemotherapy, Adjuvant,
pubmed-meshheading:20354751-Chi-Square Distribution,
pubmed-meshheading:20354751-China,
pubmed-meshheading:20354751-Disease Progression,
pubmed-meshheading:20354751-Female,
pubmed-meshheading:20354751-Humans,
pubmed-meshheading:20354751-Immunoblotting,
pubmed-meshheading:20354751-Male,
pubmed-meshheading:20354751-Middle Aged,
pubmed-meshheading:20354751-Neoplasm Metastasis,
pubmed-meshheading:20354751-Neoplasm Staging,
pubmed-meshheading:20354751-Neoplasms,
pubmed-meshheading:20354751-Surgical Procedures, Operative,
pubmed-meshheading:20354751-Thymidine Kinase,
pubmed-meshheading:20354751-Time Factors,
pubmed-meshheading:20354751-Treatment Outcome,
pubmed-meshheading:20354751-Tumor Burden,
pubmed-meshheading:20354751-Tumor Markers, Biological
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Serum thymidine kinase 1 correlates to clinical stages and clinical reactions and monitors the outcome of therapy of 1,247 cancer patients in routine clinical settings.
|
|
pubmed:affiliation |
Laboratory of Biochemistry and Molecular Biology Research, Fujian Cancer Hospital of Fujian Medical University Teaching Hospital, Fuzhou, Fujian 350014, China. yanc99@sina.com
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|
